Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator that provides integrated programs and tailored services for the pharmaceutical and biotech industries. The company was founded in 1990 through the establishment of Quotient Bioresearch and Pharmaceutical Profiles, a spin-out from the University of Nottingham. It operates as a contract development and manufacturing organization (CDMO), assisting clients from candidate selection through to commercial launch.

The company's business model centers on integrating services that are traditionally outsourced to separate entities, thereby simplifying the supply chain and accelerating development timelines. Its core service platform, Translational Pharmaceutics®, combines formulation development, real-time GMP manufacturing, and clinical testing into a single, seamless process. This integrated approach has been shown to shorten development timelines by an average of 12 months. Services include drug substance synthesis, formulation development for various dosage forms (oral, inhaled, parenteral), clinical trial manufacturing, and clinical pharmacology. The company serves a global client base ranging from small biotech firms to large multinational pharmaceutical companies.

Quotient Sciences has grown through strategic acquisitions, including Arcinova in 2021, which expanded its capabilities into drug substance manufacturing and bioanalysis. This move allowed for the full integration of drug substance, drug product, and clinical testing services under one organization. The company is led by CEO Thierry Van Nieuwenhove, who joined in October 2023, and operates from facilities in the UK and the US.

Keywords: drug development, manufacturing accelerator, CDMO, contract development manufacturing, Translational Pharmaceutics, formulation development, clinical trial manufacturing, pharmaceutical services, drug substance synthesis, clinical pharmacology, bioanalysis, GMP manufacturing, small molecule development, biotech outsourcing, pharma services, product commercialization